A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Phase 2 Completed 248 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.

Timeline

Start: 2006-05
Primary completion: 2012-09
Completion: 2014-04

Publications

Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Hamid O, O'Day SJ, Konto C, Cykowski L, McHenry MB, Wolchok JD. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol. 2014 Nov;25(11):2277-2284. doi: 10.1093/annonc/mdu441. Epub 2014 Sep 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ipilimumab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	Ipilimumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Ipilimumab	Monoclonal antibody	10 mg/kg	Intravenous

A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies

Summary

Timeline

Publications

Drugs

Indications